A Phase 2 interventional study of PNEUMOSTEM and Placebo in Severe Bronchopulmonary Dysplasia, sponsored by Medipost Co Ltd.. Completed at 2 sites in Korea, Republic of. Open to participants aged Up to 13 Days. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Medipost Co Ltd. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. PNEUMOSTEM is intended to prevent and treat BPD by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects.
362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.
This study's enrollment of 60 is close to the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.
Browse Bronchopulmonary Dysplasia studies →Medipost Co Ltd. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
at screening and randomization
at IP administration
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
Biological: PNEUMOSTEM
normal saline
Other: Placebo
human umbilical cord blood-derived mesenchymal stem cells
normal saline
Percentage of subjects who have severe BPD or are dead
Percentage of subjects who have severe BPD or are dead
Time frame: 36 weeks postmenstrual age (PMA)
Percentage of subjects who have moderate/severe BPD or are dead
Percentage of subjects who have moderate/severe BPD or are dead
Time frame: 36 weeks PMA
Percentage of subjects by severity of BPD
Percentage of subjects by severity of BPD
Time frame: prenatal 28 days/36 weeks PMA
Percentage of subjects in death due to lung disease
Percentage of subjects in death due to lung disease
Time frame: prenatal 28 days/36 weeks PMA and study end timepoint
intubation duration
intubation duration
Time frame: up to 24 weeks
ventilation duration
ventilation duration
Time frame: up to 24 weeks
continuous positive airway pressure (CPAP) treatment duration
continuous positive airway pressure (CPAP) treatment duration
Time frame: up to 24 weeks
treatment duration with supplemental oxygen
treatment duration with supplemental oxygen
Time frame: up to 24 weeks
% of subjects treated with steroid for weaning ventilator
% of subjects treated with steroid for weaning ventilator
Time frame: up to 24 weeks
Retinopathy of prematurity (ROP) with stage III or higher
number of subjects with ROP with stage III or higher
Time frame: up to 24 weeks
number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy
number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy
Time frame: up to 24 weeks
z-score
percentile for body weight, height, and head circumference
Time frame: up to 24 weeks (visit 10)
days in hospitalization
days in hospitalization
Time frame: up to 24 weeks
changes in tracheal suction fluid examination
changes in tracheal suction fluid examination
Time frame: from screening to 7 days after IP administration (visit 5)
Plan to share: Undecided
Ran from Aug 2018 to primary completion in Jan 2024, 64 months.
Of 19 phase 2 interventional studies under Bronchopulmonary Dysplasia, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 69. This study's 64 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medipost Co Ltd.